Technical Analysis for PTGX - Protagonist Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -2.23% | |
| 20 DMA Resistance | Bearish | -2.34% | |
| MACD Bullish Signal Line Cross | Bullish | -2.34% | |
| Earnings Movers | Other | -2.34% | |
| Gapped Up | Strength | -2.34% | |
| Spinning Top | Other | -0.23% | |
| Earnings Movers | Other | -0.23% | |
| Inside Day | Range Contraction | -0.23% | |
| Pocket Pivot | Bullish Swing Setup | -0.31% | |
| Outside Day | Range Expansion | -0.31% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 3 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 2 % | about 3 hours ago |
| Fell Below 10 DMA | about 3 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Autoimmune Disease Inflammatory Bowel Disease Ulcerative Colitis Ulcer Abdominal Pain Colitis Crohn's Disease Chemical Entities Hepcidin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 33.34 |
| 52 Week Low | 13.72 |
| Average Volume | 570,503 |
| 200-Day Moving Average | 21.96 |
| 50-Day Moving Average | 28.05 |
| 20-Day Moving Average | 26.18 |
| 10-Day Moving Average | 25.63 |
| Average True Range | 1.06 |
| RSI (14) | 46.52 |
| ADX | 12.39 |
| +DI | 24.54 |
| -DI | 23.06 |
| Chandelier Exit (Long, 3 ATRs) | 26.03 |
| Chandelier Exit (Short, 3 ATRs) | 27.40 |
| Upper Bollinger Bands | 28.32 |
| Lower Bollinger Band | 24.05 |
| Percent B (%b) | 0.47 |
| BandWidth | 16.34 |
| MACD Line | -0.60 |
| MACD Signal Line | -0.69 |
| MACD Histogram | 0.0919 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 27.43 | ||||
| Resistance 3 (R3) | 27.40 | 26.93 | 27.20 | ||
| Resistance 2 (R2) | 26.93 | 26.58 | 26.94 | 27.12 | |
| Resistance 1 (R1) | 26.49 | 26.36 | 26.71 | 26.52 | 27.05 |
| Pivot Point | 26.02 | 26.02 | 26.13 | 26.03 | 26.02 |
| Support 1 (S1) | 25.58 | 25.67 | 25.80 | 25.61 | 25.07 |
| Support 2 (S2) | 25.11 | 25.45 | 25.12 | 25.00 | |
| Support 3 (S3) | 24.67 | 25.11 | 24.92 | ||
| Support 4 (S4) | 24.70 |
